Regulated Expression of pdx-1 Promotes In Vitro Differentiation of Insulin-Producing Cells From Embryonic Stem Cells
- From the Division of Stem Cell Regulation Research, Osaka University Graduate School of Medicine, Suita, Japan
- Address correspondence and reprint requests to Jun-ichi Miyazaki, MD, PhD, Division of Stem Cell Regulation Research (G6), Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: jimiyaza{at}nutri.med.osaka-u.ac.jp
Abstract
Embryonic stem (ES) cells can differentiate into many cell types. Recent reports have shown that ES cells can differentiate into insulin-producing cells. However, the differentiation is not efficient enough to produce insulin-secreting cells for future therapeutic use. Pdx-1, a homeodomain-containing transcription factor, is a crucial regulator for pancreatic development. We established an ES cell line in which exogenous pdx-1 expression was precisely regulated by the Tet-off system integrated into the ROSA26 locus. Using this cell line, we examined the effect of pdx-1 expression during in vitro differentiation via embryoid body formation. The results showed that pdx-1 expression clearly enhanced the expression of the insulin 2, somatostatin, Kir6.2, glucokinase, neurogenin3, p48, Pax6, PC2, and HNF6 genes in the resulting differentiated cells. Immunohistochemical examination also revealed that insulin was highly produced in most of the differentiated ES cells. Thus, exogenous expression of pdx-1 should provide a promising approach for efficiently producing insulin-secreting cells from human ES cells for future therapeutic use in diabetic patients.
- bFGF, basic fibroblast growth factor
- DMEM, Dulbecco’s modified Eagle’s medium
- Dox, doxytetracycline
- EB, embryoid body
- EGFB, enhanced green fluorescent protein
- ES, embryonic stem
- IRES, internal ribosome entry site
- LIF, leukemia inhibitory factor
- tTA, tetracycline-regulated transcriptional activator
- TUNEL, transferase-mediated dUTP nick-end labeling
Footnotes
-
- Accepted January 16, 2004.
- Received July 31, 2003.
- DIABETES














